NasdaqCM - Nasdaq Real Time Price USD

China SXT Pharmaceuticals, Inc. (SXTC)

1.1050 +0.0650 (+6.25%)
As of 1:38 PM EDT. Market Open.
Loading Chart for SXTC
DELL
  • Previous Close 1.0400
  • Open 1.0100
  • Bid 0.7992 x 200
  • Ask 1.3000 x 200
  • Day's Range 1.0100 - 1.1350
  • 52 Week Range 0.9400 - 9.3750
  • Volume 240,114
  • Avg. Volume 1,007,036
  • Market Cap (intraday) 624,914
  • Beta (5Y Monthly) 1.10
  • PE Ratio (TTM) --
  • EPS (TTM) -26.9600
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

www.sxtchina.com

78

Full Time Employees

March 31

Fiscal Year Ends

Recent News: SXTC

Performance Overview: SXTC

Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SXTC
72.17%
S&P 500
9.56%

1-Year Return

SXTC
80.00%
S&P 500
26.71%

3-Year Return

SXTC
96.16%
S&P 500
27.07%

5-Year Return

SXTC
99.74%
S&P 500
85.84%

Compare To: SXTC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SXTC

Valuation Measures

Annual
As of 5/13/2024
  • Market Cap

    588.15k

  • Enterprise Value

    -7.73M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.28

  • Price/Book (mrq)

    0.12

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -45.75%

  • Return on Equity (ttm)

    -141.60%

  • Revenue (ttm)

    1.7M

  • Net Income Avi to Common (ttm)

    -14.14M

  • Diluted EPS (ttm)

    -26.9600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.47M

  • Total Debt/Equity (mrq)

    70.37%

  • Levered Free Cash Flow (ttm)

    -400.4k

Research Analysis: SXTC

Company Insights: SXTC

Research Reports: SXTC

People Also Watch